Page 1 | Search Results | Blood | American Society of Hematology

1-15 of 15

Sort by

Sort Order Select

Journal Articles

NGS better discriminates true MRD positivity for the risk stratification of childhood ALL treated on an MRD-based protocol

Michael Svaton, Aneta Skotnicova, Leona Reznickova, Andrea Rennerova, Tatana Valova, Michaela Kotrova, Vincent H. J. van der Velden, Monika Brüggemann, Nikos Darzentas, Anton W. Langerak, Jan Zuna, Jan Stary, Jan Trka, Eva Fronkova

Blood (2023) 141 (5): 529–533.

https://doi.org/10.1182/blood.2022017003

Published: 2023

Includes: Supplemental data

Journal Articles

A phase 1 study of inotuzumab ozogamicin in pediatric relapsed/refractory acute lymphoblastic leukemia (ITCC-059 study)

Blood (2021) 137 (12): 1582–1590.

https://doi.org/10.1182/blood.2020007848

Published: 2021

Includes: Supplemental data

Journal Articles

Standardized flow cytometry for highly sensitive MRD measurements in B-cell acute lymphoblastic leukemia

Blood (2017) 129 (3): 347–357.

https://doi.org/10.1182/blood-2016-07-726307

Published: 2017

Includes: Supplemental data

Journal Articles

Minimal residual disease diagnostics in acute lymphoblastic leukemia: need for sensitive, fast, and standardized technologies

Jacques J. M. van Dongen, Vincent H. J. van der Velden, Monika Brüggemann, Alberto Orfao

Blood (2015) 125 (26): 3996–4009.

https://doi.org/10.1182/blood-2015-03-580027

Published: 2015

Journal Articles

B-cell prolymphocytic leukemia: a specific subgroup of mantle cell lymphoma

Vincent H. J. van der Velden, Patricia G. Hoogeveen, Dick de Ridder, Magdalena Schindler-van der Struijk, Menno C. van Zelm, Mathijs Sanders, Dennis Karsch, H. Berna Beverloo, King Lam, Alberto Orfao, Pieternella J. Lugtenburg, Sebastian Böttcher, Jacques J. M. van Dongen, Anton W. Langerak, Mies Kappers-Klunne, Kirsten van Lom

Blood (2014) 124 (3): 412–419.

https://doi.org/10.1182/blood-2013-10-533869

Published: 2014

Includes: Supplemental data

Journal Articles

Pediatric acute myeloid leukemia with t(8;16)(p11;p13), a distinct clinical and biological entity: a collaborative study by the International-Berlin-Frankfurt-Münster AML-study group

Blood (2013) 122 (15): 2704–2713.

https://doi.org/10.1182/blood-2013-02-485524

Published: 2013

Includes: Supplemental data

Journal Articles

Independent prognostic value of BCR-ABL1-like signature and IKZF1 deletion, but not high CRLF2 expression, in children with B-cell precursor ALL

Arian van der Veer, Esmé Waanders, Rob Pieters, Marieke E. Willemse, Simon V. Van Reijmersdal, Lisa J. Russell, Christine J. Harrison, William E. Evans, Vincent H. J. van der Velden, Peter M. Hoogerbrugge, Frank Van Leeuwen, Gabriele Escherich, Martin A. Horstmann, Leila Mohammadi Khankahdani, Dimitris Rizopoulos, Hester A. De Groot-Kruseman, Edwin Sonneveld, Roland P. Kuiper, Monique L. Den Boer

Blood (2013) 122 (15): 2622–2629.

https://doi.org/10.1182/blood-2012-10-462358

Published: 2013

Includes: Supplemental data

Journal Articles

Leukemia surfaceome analysis reveals new disease-associated features

Paulina Mirkowska, Andreas Hofmann, Lukasz Sedek, Lucie Slamova, Ester Mejstrikova, Tomasz Szczepanski, Maike Schmitz, Gunnar Cario, Martin Stanulla, Martin Schrappe, Vincent H. J. van der Velden, Beat C. Bornhauser, Bernd Wollscheid, Jean-Pierre Bourquin

Blood (2013) 121 (25): e149–e159.

https://doi.org/10.1182/blood-2012-11-468702

Published: 2013

Includes: Supplemental data

Journal Articles

High GATA2 expression is a poor prognostic marker in pediatric acute myeloid leukemia

Maaike Luesink, Iris H. I. M. Hollink, Vincent H. J. van der Velden, Ruth H. J. N. Knops, Jan B. M. Boezeman, Valérie de Haas, Jan Trka, Andre Baruchel, Dirk Reinhardt, Bert A. van der Reijden, Marry M. van den Heuvel-Eibrink, C. Michel Zwaan, Joop H. Jansen

Blood (2012) 120 (10): 2064–2075.

https://doi.org/10.1182/blood-2011-12-397083

Published: 2012

Includes: Supplemental data

Journal Articles

Human telomere disease due to disruption of the CCAAT box of the TERC promoter

Anna M. Aalbers, Sachiko Kajigaya, Marry M. van den Heuvel-Eibrink, Vincent H. J. van der Velden, Rodrigo T. Calado, Neal S. Young

Blood (2012) 119 (13): 3060–3063.

https://doi.org/10.1182/blood-2011-10-383182

Published: 2012

Journal Articles

Identification of distinct prognostic subgroups in low- and intermediate-1–risk myelodysplastic syndromes by flow cytometry

Arjan A. van de Loosdrecht, Theresia M. Westers, August H. Westra, Angelika M. Dräger, Vincent H. J. van der Velden, Gert J. Ossenkoppele

Blood (2008) 111 (3): 1067–1077.

https://doi.org/10.1182/blood-2007-07-098764

Published: 2008

Journal Articles

CD33 expression and P-glycoprotein–mediated drug efflux inversely correlate and predict clinical outcome in patients with acute myeloid leukemia treated with gemtuzumab ozogamicin monotherapy

Roland B. Walter, Ted A. Gooley, Vincent H. J. van der Velden, Michael R. Loken, Jacques J. M. van Dongen, David A. Flowers, Irwin D. Bernstein, Frederick R. Appelbaum

Blood (2007) 109 (10): 4168–4170.

https://doi.org/10.1182/blood-2006-09-047399

Published: 2007

Journal Articles

Vδ2-Jα rearrangements are frequent in precursor-B–acute lymphoblastic leukemia but rare in normal lymphoid cells

Tomasz Szczepański, Vincent H. J. van der Velden, Patricia G. Hoogeveen, Maaike de Bie, Daniëlle C. H. Jacobs, Elisabeth R. van Wering, Jacques J. M. van Dongen

Blood (2004) 103 (10): 3798–3804.

https://doi.org/10.1182/blood-2003-08-2952

Published: 2004

Journal Articles

Possible link between unique chemokine and homing receptor expression at diagnosis and relapse location in a patient with childhood T-ALL

Nicola E. Annels, Annemieke J. Willemze, Vincent H. J. van der Velden, Claudia M. J. M. Faaij, Elisabeth van Wering, Daisy M. D. S. Sie-Go, R. Maarten Egeler, Maarten J. D. van Tol, Tom Révész

Blood (2004) 103 (7): 2806–2808.

https://doi.org/10.1182/blood-2003-06-1812

Published: 2004

Journal Articles

Targeting of the CD33-calicheamicin immunoconjugate Mylotarg (CMA-676) in acute myeloid leukemia: in vivo and in vitro saturation and internalization by leukemic and normal myeloid cells

Vincent H. J. van der Velden, Jeroen G. te Marvelde, Patricia G. Hoogeveen, Irwin D. Bernstein, Adriaan B. Houtsmuller, Mark S. Berger, Jacques J. M. van Dongen

Blood (2001) 97 (10): 3197–3204.

https://doi.org/10.1182/blood.V97.10.3197

Published: 2001

NARROW

NGS better discriminates true MRD positivity for the risk stratification of childhood ALL treated on an MRD-based protocol

A phase 1 study of inotuzumab ozogamicin in pediatric relapsed/refractory acute lymphoblastic leukemia (ITCC-059 study)

Standardized flow cytometry for highly sensitive MRD measurements in B-cell acute lymphoblastic leukemia

Minimal residual disease diagnostics in acute lymphoblastic leukemia: need for sensitive, fast, and standardized technologies

B-cell prolymphocytic leukemia: a specific subgroup of mantle cell lymphoma

Pediatric acute myeloid leukemia with t(8;16)(p11;p13), a distinct clinical and biological entity: a collaborative study by the International-Berlin-Frankfurt-Münster AML-study group

Independent prognostic value of BCR-ABL1-like signature and IKZF1 deletion, but not high CRLF2 expression, in children with B-cell precursor ALL

Leukemia surfaceome analysis reveals new disease-associated features

High GATA2 expression is a poor prognostic marker in pediatric acute myeloid leukemia

Human telomere disease due to disruption of the CCAAT box of the TERC promoter

Identification of distinct prognostic subgroups in low- and intermediate-1–risk myelodysplastic syndromes by flow cytometry

CD33 expression and P-glycoprotein–mediated drug efflux inversely correlate and predict clinical outcome in patients with acute myeloid leukemia treated with gemtuzumab ozogamicin monotherapy

Vδ2-Jα rearrangements are frequent in precursor-B–acute lymphoblastic leukemia but rare in normal lymphoid cells

Possible link between unique chemokine and homing receptor expression at diagnosis and relapse location in a patient with childhood T-ALL

Targeting of the CD33-calicheamicin immunoconjugate Mylotarg (CMA-676) in acute myeloid leukemia: in vivo and in vitro saturation and internalization by leukemic and normal myeloid cells

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only